Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 65
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Hyry, Hanna I. Cox, Timothy M. and Roos, Jonathan C. P. 2016. Saving orphan drug legislations: misconceptions and clarifications. Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 16, Issue. 1, p. 111.


    Kolasa, Katarzyna Zwolinski, Krzysztof M. Kalo, Zoltan and Hermanowski, Tomasz 2016. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs. Orphanet Journal of Rare Diseases, Vol. 11, Issue. 1,


    Logviss, Konstantins Krievins, Dainis and Purvina, Santa 2016. Impact of orphan drugs on Latvian budget. Orphanet Journal of Rare Diseases, Vol. 11, Issue. 1,


    Mikami, Koichi Kent, Alastair and Haddow, Gill 2016. Genomics and Society.


    van de Wetering, E. J. van Exel, N. J. A. Rose, J. M. Hoefman, R. J. and Brouwer, W. B. F. 2016. Are some QALYs more equal than others?. The European Journal of Health Economics, Vol. 17, Issue. 2, p. 117.


    Zelei, Tamás Molnár, Mária J. Szegedi, Márta and Kaló, Zoltán 2016. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. Orphanet Journal of Rare Diseases, Vol. 11, Issue. 1,


    Boon, Wouter Martins, Luis and Koopmanschap, Marc 2015. Governance of conditional reimbursement practices in the Netherlands. Health Policy, Vol. 119, Issue. 2, p. 180.


    Graf von der Schulenburg, J.-Matthias and Frank, Martin 2015. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. The European Journal of Health Economics, Vol. 16, Issue. 2, p. 113.


    Grepstad, Mari and Kanavos, Panos 2015. A comparative analysis of coverage decisions for outpatient pharmaceuticals: Evidence from Denmark, Norway and Sweden. Health Policy, Vol. 119, Issue. 2, p. 203.


    Gutierrez, Laura Patris, Julien Hutchings, Adam and Cowell, Warren 2015. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe. Orphanet Journal of Rare Diseases, Vol. 10, Issue. 1,


    Kanters, T. A. Redekop, W. K. Kruijshaar, M. E. van der Ploeg, A. T. Rutten-van Mölken, M. P. M. H. and Hakkaart, L. 2015. Comparison of EQ-5D and SF-6D utilities in Pompe disease. Quality of Life Research, Vol. 24, Issue. 4, p. 837.


    McDonald, Heather Charles, Cathy Elit, Laurie and Gafni, Amiram 2015. Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes?. PharmacoEconomics, Vol. 33, Issue. 3, p. 235.


    Meacock, Rachel Harrison, Mark McElhone, Kathleen Abbott, Janice Haque, Sahena Bruce, Ian and Teh, Lee-Suan 2015. Mapping the disease-specific LupusQoL to the SF-6D. Quality of Life Research, Vol. 24, Issue. 7, p. 1749.


    Onakpoya, Igho J Spencer, Elizabeth A Thompson, Matthew J and Heneghan, Carl J 2015. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open, Vol. 5, Issue. 6, p. e007199.


    Park, Taehwan Griggs, Scott K. and Suh, Dong-Churl 2015. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review. BioDrugs, Vol. 29, Issue. 4, p. 259.


    Paulden, Mike Stafinski, Tania Menon, Devidas and McCabe, Christopher 2015. Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework. PharmacoEconomics, Vol. 33, Issue. 3, p. 255.


    Schuller, Y. Hollak, C. E. M. and Biegstraaten, M. 2015. The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. Orphanet Journal of Rare Diseases, Vol. 10, Issue. 1,


    Wonder, Michael and Chin, Geoffrey 2015. What impact does ‘conventional’ economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005–2012). Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 15, Issue. 5, p. 843.


    2015. Conciliar eficiencia y equidad. medicamentos huérfanos para enfermedades raras. Revista Médica Clínica Las Condes, Vol. 26, Issue. 4, p. 533.


    Abrahamyan, Lusine Willan, Andrew R. Beyene, Joseph Mclimont, Marjorie Blanchette, Victor and Feldman, Brian M. 2014. Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A. Journal of General Internal Medicine, Vol. 29, Issue. S3, p. 767.


    ×
  • International Journal of Technology Assessment in Health Care, Volume 23, Issue 1
  • January 2007, pp. 36-42

Assessing the economic challenges posed by orphan drugs

  • Michael F. Drummond (a1), David A. Wilson (a2), Panos Kanavos (a3), Peter Ubel (a4) and Joan Rovira (a5)
  • DOI: http://dx.doi.org/10.1017/S0266462307051550
  • Published online: 01 January 2007
Abstract

Historically, patients with rare diseases have been underserved by commercial drug development. In several jurisdictions, specific legislation has been enacted to encourage the development of drugs for rare diseases (orphan drugs), which would otherwise not be commercially viable. However, because of the small market, these drugs are often very expensive. Under the standard methods of health technology assessment (HTA) incorporating economic evaluation, orphan drugs do not usually prove to be cost-effective and this, coupled with their high cost, means that funding and patient access may be limited. However, these restrictions may not be in line with societal preferences. Therefore, this study discusses whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs and outlines a research agenda to help understand the societal value of orphan drugs and issues surrounding their development, funding, and use.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: